‘The EPO can manage it—I’m baffled why the UPC can’t’: Test case challenges court’s ‘request for access’ rule
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Patent term compensation controversies in Mexico
An ambiguous decision by the Supreme Court has paved the way for frivolous petitions for compensation and clarity is needed, say Daniel Sanchez and Karla Olvera of Olivares.
The new IP battleground in CRISPR-Cas
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
How to patent biological materials from 3D printing
Securing IP protection in Brazil for the ‘bio-ink’ used to print new human tissue has challenges but composition is key, say Priscila Kashiwabara and Breno Souza of Kasznar Leonardos.
A hard lesson learnt: Commonwealth v Sanofi
The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction delays a generic's launch but the patent is invalidated or there is a finding of non-infringement.
First few months of the Unified Patent Court: a review
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Is the ITC the right venue for trade secrets theft?
If the right steps are taken, the US International Trade Commission is an attractive option for firms fearing the loss of their valuable IP, say Mary Prendergast, Mark Whitaker and Nicole Ang of Morrison Foerster.
'Cellect': why patent term adjustment is ripe for review
In part 2 of articles assessing the impact of 'Cellect v Samsung', Vincent Shier of Haynes Boone now sets out what the future may hold—both for this unusual case, as well as judicial doctrine in general.
Why Fed Circ's 'Cellect' decision cannot be ignored
A Federal Circuit decision provides lessons on why inaction over patent terms may risk incurable invalidation of important patents, writes Vincent Shier of Haynes Boone.
Regimen patents in Japan: LCM failures and successes
Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents.
